<?xml version='1.0' encoding='utf-8'?>
<document id="21779389"><sentence text="Proton pump inhibitors inhibit metformin uptake by organic cation transporters (OCTs)."><entity charOffset="31-40" id="DDI-PubMed.21779389.s1.e0" text="metformin" /></sentence><sentence text="Metformin, an oral insulin-sensitizing drug, is actively transported into cells by organic cation transporters (OCT) 1, 2, and 3 (encoded by SLC22A1, SLC22A2, or SLC22A3), which are tissue specifically expressed at significant levels in various organs such as liver, muscle, and kidney"><entity charOffset="0-9" id="DDI-PubMed.21779389.s2.e0" text="Metformin" /></sentence><sentence text=" Because metformin does not undergo hepatic metabolism, drug-drug interaction by inhibition of OCT transporters may be important"><entity charOffset="9-18" id="DDI-PubMed.21779389.s3.e0" text="metformin" /></sentence><sentence text=" So far, comprehensive data on the interaction of proton pump inhibitors (PPIs) with OCTs are missing although PPIs are frequently used in metformin-treated patients"><entity charOffset="139-148" id="DDI-PubMed.21779389.s4.e0" text="metformin" /></sentence><sentence text=" Using in silico modeling and computational analyses, we derived pharmacophore models indicating that PPIs (i" /><sentence text="e" /><sentence text=" omeprazole, pantoprazole, lansoprazole, rabeprazole, and tenatoprazole) are potent OCT inhibitors"><entity charOffset="1-11" id="DDI-PubMed.21779389.s7.e0" text="omeprazole" /><entity charOffset="13-25" id="DDI-PubMed.21779389.s7.e1" text="pantoprazole" /><entity charOffset="27-39" id="DDI-PubMed.21779389.s7.e2" text="lansoprazole" /><entity charOffset="41-52" id="DDI-PubMed.21779389.s7.e3" text="rabeprazole" /><entity charOffset="58-71" id="DDI-PubMed.21779389.s7.e4" text="tenatoprazole" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e0" e2="DDI-PubMed.21779389.s7.e0" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e0" e2="DDI-PubMed.21779389.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e0" e2="DDI-PubMed.21779389.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e0" e2="DDI-PubMed.21779389.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e0" e2="DDI-PubMed.21779389.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e1" e2="DDI-PubMed.21779389.s7.e1" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e1" e2="DDI-PubMed.21779389.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e1" e2="DDI-PubMed.21779389.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e1" e2="DDI-PubMed.21779389.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e2" e2="DDI-PubMed.21779389.s7.e2" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e2" e2="DDI-PubMed.21779389.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e2" e2="DDI-PubMed.21779389.s7.e4" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e3" e2="DDI-PubMed.21779389.s7.e3" /><pair ddi="false" e1="DDI-PubMed.21779389.s7.e3" e2="DDI-PubMed.21779389.s7.e4" /></sentence><sentence text=" We then established stably transfected cell lines expressing the human uptake transporters OCT1, OCT2, or OCT3 and tested whether these PPIs inhibit OCT-mediated metformin uptake in vitro"><entity charOffset="163-172" id="DDI-PubMed.21779389.s8.e0" text="metformin" /></sentence><sentence text=" All tested PPIs significantly inhibited metformin uptake by OCT1, OCT2, and OCT3 in a concentration-dependent manner"><entity charOffset="41-50" id="DDI-PubMed.21779389.s9.e0" text="metformin" /></sentence><sentence text=" Half-maximal inhibitory concentration values (IC(50)) were in the low micromolar range (3-36 ÂµM) and thereby in the range of IC(50) values of other potent OCT drug inhibitors" /><sentence text=" Finally, we tested whether the PPIs are also transported by OCTs, but did not identify PPIs as OCT substrates" /><sentence text=" In conclusion, PPIs are potent inhibitors of the OCT-mediated metformin transport in vitro"><entity charOffset="63-72" id="DDI-PubMed.21779389.s12.e0" text="metformin" /></sentence><sentence text=" Further studies are needed to elucidate the clinical relevance of this drug-drug interaction with potential consequences on metformin disposition and/or efficacy"><entity charOffset="125-134" id="DDI-PubMed.21779389.s13.e0" text="metformin" /></sentence><sentence text="" /></document>